Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

被引:1083
作者
Takemoto, M
Liao, JK
机构
[1] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
endothelium; vascular smooth muscle; platelets; atherosclerosis; inflammation;
D O I
10.1161/hq1101.098486
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitors or statins are potent inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the beneficial effects of statins in the primary and secondary prevention of coronary heart disease. However, the overall clinical benefits observed with statin therapy appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels. Indeed, recent experimental and clinical evidence indicates that some of the cholesterol-independent or "pleiotropic" effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, and decreasing oxidative stress and vascular inflammation. Many of these pleiotropic effects of statins are mediated by their ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules. In particular, the inhibition of small GTP-binding proteins, Rho, Ras, and Rac, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in mediating the direct cellular effects of statins on the vascular wall.
引用
收藏
页码:1712 / 1719
页数:8
相关论文
共 120 条
  • [1] Aikawa M, 2001, CIRCULATION, V103, P276
  • [2] Alternative binding assay of GP IIb/IIIa antagonists with a nonradioactive labeling method of platelets
    Alfón, J
    de Arriba, AF
    Gómez-Casajús, LA
    Merlos, M
    [J]. THROMBOSIS RESEARCH, 2001, 102 (03) : 247 - 253
  • [3] Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
    Alfon, J
    Royo, T
    Garcia-Moll, X
    Badimon, L
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (07) : 1812 - 1817
  • [4] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION
    ANDERSON, TJ
    MEREDITH, IT
    YEUNG, AC
    FREI, B
    SELWYN, AP
    GANZ, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) : 488 - 493
  • [5] Platelet alpha(2)-adrenergic receptors in hypercholesterolemia: Relationship between binding studies and epinephrine-induced platelet aggregation
    Baldassarre, D
    Mores, N
    Colli, S
    Pazzucconi, F
    Sirtori, CR
    Tremoli, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (06) : 684 - 691
  • [6] THE ACUTE-PHASE RESPONSE
    BAUMANN, H
    GAULDIE, J
    [J]. IMMUNOLOGY TODAY, 1994, 15 (02): : 74 - 80
  • [7] Non-lipid-related effects of statins
    Bellosta, S
    Ferri, N
    Bernini, F
    Paoletti, R
    Corsini, A
    [J]. ANNALS OF MEDICINE, 2000, 32 (03) : 164 - 176
  • [8] Bellosta S, 2000, DIABETES CARE, V23, pB72
  • [9] HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
    Bourcier, T
    Libby, P
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) : 556 - 562
  • [10] Cell cycle progression - New therapeutic target for vascular proliferative disease
    Braun-Dullaeus, RC
    Mann, MJ
    Dzau, VJ
    [J]. CIRCULATION, 1998, 98 (01) : 82 - 89